Method of preparing substituted derivatives of n-(phenyxyalkyl)-amidazole ot their salts

专利摘要:
N-(mono or disubstituted Phenoxyalkyl)imidazoles and the pharmaceutically acceptable acid addition salts thereof are able to selectively inhibit the action of the thromboxane synthetase enzyme without significantly inhibiting the action of the prostacycline synthetase or cyclooxygenase enzymes and are thus useful in the treatment of ischaemic heart disease, stroke, transient ischaemic attack, thrombosis migraine and the vascular complications of diabetes.
公开号:SU878195A3
申请号:SU792854456
申请日:1979-12-12
公开日:1981-10-30
发明作者:Эдвард Кросс Питер；Питер Диккинсон Роджер
申请人:Пфайзер Корпорейшн (Фирма)；
IPC主号:

专利说明:

(54) METHOD FOR OBTAINING SUBSTITUTED DERIVATIVES (H-PHENOXYLKYL) IMIDAZOL OR THEIR SALTS , CG, jR2- ,, OCH ,, C02: R, CONHR, CHs CONHR OCH2.CONHR5, CON (R) 2.,; CH2.CON (R) 2, (R4) 2,, P2, / Z 9 WVH -wiivi / 2. NHR,, tetrazolyl, SND -tetrazolyl or OCH —themethamide, Rolyl; R — H, C — C4-alkyl, C —C-Alkoxy 2 or halogen; R — H or C-C4-alkyl; , C-C4-alkyl, C-C-alkyl-noyl, C-C-alkylsulfonyl, CM, benzoyl or benzoylsulfonyl, in which the benzene ring may be substituted by one or several C-C-alkyl, C-C-alkoxy, or CF, or halogen groups; R-C-C-alkyl or two or two, together with the nitrogen atom to which they are attached, form pyrolidino, piperidino or morpholino; R-H , C-C-alkanoyl,, -alkoxycarbonyl, carbamoyl or C-Cd-alkylcarbamoyl; n - 2 or 3, or their salts with biological activity, which can be used in the treatment of thrombosis, ischemic heart disease, paralysis, migraine, and vascular diabetes complications. The reaction of reacting amines with halogen-substituted compounds ij is known. The purpose of the invention is the synthesis of new compounds with valuable properties. This goal is achieved based on a known reaction method for the preparation of compounds of formula I, consisting in the interaction of imidazole with an alkali metal hydride and a compound of the general formula. Hal-iCH2) -0-, where n, R and R are as defined above; Hal - chlorine, bromine or iodine, with the separation of the target product in free form or in salt form. The product obtained is isolated by known methods, for example by removal of the solvent under vacuum, extraction or recrystallization. The starting compounds of general formula I are generally known compounds or can be obtained from appropriately substituted phenols by reaction with sodium hydride and ari sulfonyloxyethyl or propyl halide. Compounds of general formula I selectively suppress the activity of the enzyme thromboxane synthetase, without having PS substantially affecting the activity of the enzymes prostacyclin synthetase or cyclo-oxygenase. Therefore, these compounds can be used in clinical treatment based on the imbalance of the ratio of prostacyclin-thromboxane D. The test compound is preincubated with fermento1 1 for 5 minutes, and its ability to suppress the activity of the enzyme, thromboxane synthetase is measured using induced component TXA2 isometric voltage reduction. By testing the compounds in this way, it has been established that they have a selective ability to inhibit the activity of the enzyme thromboxane synthetase. The results of such tests are given in table. 1, where the concentration of each compound is given, for which there are 50% changes in the effect of the corresponding enzyme on the isometric voltage, i.e. 50% inhibition of the activity of such an enzyme. In addition, ratios of molar concentrations that have a 50% inhibitory effect on enzyme prostacyclin synthetase and thromboxane synthetase are given. These results indicate the ability of compounds to inhibit the activity of the latter enzyme relative to the first. The data given in table. 1, it is shown that all tested compounds have a 50% inhibitory effect on the thromboxane rnthetase enzyme at a molar concentration of lOjOxlO or less, and some have a 50% inhibitory effect at concentrations of 10 or less. Of the compounds tested for inhibitory action. On the enzyme cyclo-oxygenase, none has a 50% inhibitory effect. at molar concentrations of 10 or less; their ability to suppress the activity of this enzyme is at least 4500 times less, and in some cases more than 10,000 times less than their ability to exert an inhibitory effect on the enzyme thromboxane synthetase. Of the compounds tested for the inhibitory effect on the enzyme prostacyclin synth.tatase, none have a 50% inhibitory effect at molar concentrations less than 2000 times higher than molar concentrations at which they have a 50% inhibitory effect on the enzyme thromboxane synthetase, i.e. all of them, at least 2000 times, have a stronger inhibitory effect on thromboxane synthetase than on prostacyclin synthetase. Laboratory tests conducted to measure the inhibitory effect on platelet adhesion in human blood suggest that the compounds are effective in clinical use as antithrombotic agents. In these trials, both effective clinical agents, aspirin and sulfinpyrazone, show inhibitory activity in the laboratory with respect to many aggregating agents. Several tests have been carried out in real conditions on animals in order to assess the effectiveness of antithrombotic activity. Intravenous administration of arachidonic acid results in the death of rabbits as a result of blood platelets sticking together and pulmonary embolism. Again, both effective clinical agents, aspirin and sulfinpyrazone, prevent lethal outcome in rabbits from the injection. Sulfinpyrazone also prevents the aggregation of blood platelets in the outer corpus of the rat abdominal aorta. Example 1. 4-Carbamoylphenoxy) ethyl Dimidazole. Sodium hydride (14.4 g, 50% suspension in mineral oil) is carefully added to the stirred and cooled solution of amidazole (20.4 g in dry N, N-dimethylformamide (YuOml. After the active reaction, at the initial stage, the mixture is heated to which is maintained for 10 minutes and then stirred at room temperature for another 1 hour. Then a solution of 4- (2-chloroethoxy benzamide (60.0 g in a minimum volume of .N, N-dimethylformamide) is added and the mixture is heated to 100 C. For 5.5 hours. The solvent is evaporated and the residue is poured into water. The mixture is not extracted how many times chloroform, combined chloroform extracts
dried over magnesium sulphate and evaporated to form a mixture of oil and solid material. The mixture is triturated with ether and the solid is collected and crystallized from the mixture.
methanol and ethyl acetate, resulting in (4-carbamoylphenoxy) ethyl imidazole (35.2 g), mp, 148-149 ° C.
Found,% s With 62,25) H 5,61,
N 18.54;
Calculated, 62,32; H 5.67, N 18.17.
Examples 2-15. The compounds were prepared analogously to example 1, but instead of 4- (2-chloroethoxy) benzamide, appropriately substituted (2-chloroethoxy) benzene was used.
Characteristics of the compounds obtained are given in table. 2 and 3.
Example 16. (4-Carbox phenoxy) ethyl j imidazole hydrochloride.
A solution of 1- {2-C4-carbamoylphenoxy) ethyl imidazole (4.5 g in 5N hydrochloric acid solution (20 ml) is heated for 2 hours and then the solution is allowed to cool. The resulting solid is separated by filtration it is imidazole hydrochloride (4.55 g), mp 233-235 ° C (increases to 239-241 ° C after crystallization from acetic acid).
Found,%: C 53.93) H 4.99,
N 10.91;
C-izH iNiO HCl
Calculated,%: C 53.64; H 4.88, N 10.43.
Example 17, (2-carboxophenoxy) ethyl 3 imidazole hydrochloride.
A solution of 1- 2- (2-ethoxycarbonylfex) ethyl 3-imidazole (5.1 g; obtained in the treatment of the attached maleate with sodium hydroxide with subsequent extraction with ethyl acetate in 5N hydrochloric acid (30 ml) is heated in a steam bath for 8h and then evaporated. The residue is crystallized from isopropanol, resulting in
receive (2-carboxyphenoxy) floor imidazole hydrochloride. 3,08 g, so pl. 138-139 ° C
Found,%: C 53.61) H 4.88, N 10.46; C aHjiN Oj HCI
Calculated,%: C 53.64; H 4.88; N 10.43,
Example 18. 1-imidazolyl) ethoxy 3 phenoxyacetic acid hydrochloride.
A solution of ethyl 4- 2- (l-imidazolyl) -toxy-phenoxyacetate (1.6 g) obtained by treating the fumarate attached with sodium hydroxide followed by extraction with ethyl acetate in 5N solution; hydrochloric acid C10 ml is heated on the steam bath for 18 h, and then evaporated. The residue is crystallized from acetonitrile, resulting in the formation of the hydrochloride (1-imidaeolyl) ethoxy. Phenoxyacetic acid Co, 72 g, m.p. 162-164 ° C,
Found%: C 52.10 / H 4.96, N 9.65J
Calculated,%: C 52.27j H 5.06, N 9.38,
Example 19 Hydrochloride - (1-imidazolyl) ethoxy phenyl acetate hydrochloride (3.5 g in 5 N, hydrochloric acid solution (20 ml) is heated in a steam bath for 6 hours and the sting is evaporated. The residue crystallizes from isopropanol, resulting in the formation of hydrochloride (1-imidazolyl) ethoxy 3 phenylacetic acid, mp 146-147 C.
Found,%: C 54.69, H 5.25)
N 9, in;
 “C1, Calculated,%: C 55.22; H 5.35;
N 9.91.
Example 20. (4-Carboxy-2-chlorophenoxy ethyl imidazole.
The mixture (4-carboxy-2-chlorophenoxyethyl imidazole (115 mg) in water (6.25 ml) is heated in a steam bath for 18 hours. The resulting solution is acidified with acetic acid and evaporated to small volume. The solid is separated by filtration , washed with water and crystallized from water, resulting in the formation of 1- 2- (4-car5oxy-2-chlorophenoxy1 ethyl imidazole (65 mg /, m.p., 204 ° C,
Na, id,%: C 53.44 H 4.15, N 10.52; .H2YClN20-i
Calculated,%: C 54.04, H 4.16, N 10.51.
Example 21. (3-carboxyphenoxy) ethyl imidazole hydrochloride,
A mixture of (z-cyanophenoxy) ethyl imidazole hydrochloride (2.0 g) and 5 n sodium hydroxide solution is heated on the steam bath for 6 hours, after which a clear solution is formed. The solution is acidified with dilute hydrochloric acid and evaporated to dryness. The residue is extracted with hot acetic acid and the solution is filtered and evaporated. Then it is crystallized from acetic acid, which results in the formation of hydrochloride (3-carboxyphenoxy ethyl imidazole, mp 232-233 C.
Found,%: C 53.13; H 4.69, N 10.68; CjifMiNj Og-HCl
Calculated: C 53.64; H 4.88; N 10.43,
Example 22. 1- 2- (4-Tetrazol-5-yl-phenoxy) ethyl imidazole.
A mixture of 1-.2- {4-cyanophenoxy; ethyl) imidazole X 2.1 g), sodium azide (3.25 g and ammonium chloride (, 2.67 g) in dry N N-dimethylformamide (26 ml) in a steam bath for 22 h. The solution is evaporated and the residue is washed with chloroform. Extract chloroform is filtered and evaporated, and the residue is crystallized from an aqueous solution of ethanol, resulting in the formation of 1- 2- (4-tetrazole-5-yl-phenoxn) ethyl imidazole (0.81 g), so pl. 1ab-197 C .
Found,%: C 56.30; H 4.76 / N 33.20, C zH iNfcO
Calculated,%: C 56.24; H 4.72,
N 32.80. .
Example 23. (1-Imilazolyl) ethoxy j-phenoxyacetamide,
A mixture of ethyl free base (1-imidazolyl ethoxy phenoxyacetate (1.0 g), ethanol {10 ml) and concentrated ammonia solution (20 ml) was kept at room temperature for 20 hours, after which a clear solution was obtained. The solution is evaporated to a residue, crystallized twice from 2-butanone, resulting in the formation of (1-imidazolyl} ethoxy phenoxyacetamide (.0.38 g; mp. 123-124 ° C.
Found,%: C 59.70, H 5.77;
N 16.26,
Calculated,%: C 59.76; H 5.79)
N 16.08
Example 24. 1- 2- (4g-M Methylcarbamoylphenoxy) ethyl imidazole,
Thionyl chloride (1, O ml is added dropwise to an intermixed mixture of {4-carboxyphenoxy) ethyl Zimidazo hydrochloride (1.0 g) and dry N N-dimethylformamide (5 ml) at room temperature. The resulting clear solution is stirred for 5 hours, added dropwise to a stirred solution of a 40% aqueous solution of methylamine (20 ml) and the resulting mixture is evaporated to dryness. The residue is then stirred in water and the solution is made alkaline by the addition of sodium bicarbonate. The mixture is evaporated and the residue is extracted with hot ethyl acetate. The extract is filtered and evaporated with hot ethyl acetate, whereby an oil is formed which solidifies on aging. The solid crystallizes from ethyl acetate to form 1-12C-M-methylcarbamoylphenoxy) ethyl imidazole (O, 68 g, mp 132-133 ° C.,
Found,%: C 63.41; H 6.14,
N 17.24;
with "n MaOi,
Calculated,%: C 63.6Gf H 6.16,
N 17.13,
Example 25. (4-N N-5H methylcarboylphenoxy) ethyl imidazrl.
Sequential processing. (4-carboxyphenoxy) ethyl Z-IMidazole, C1-hydrochloride, -0 g) with thionyl chloride (1/0 ml and 50% aqueous dimethylamine solution (20 ml) according to example
24 gives (4-N N-dimethylcarbamoylphenoxy) ethyl Dimidazole, which is isolated as fumarate attached, m.p. 113-115 C (from ethyl acetate).
Found,%: C 57.11; H 5.52;
N 11.05;
. C H T jOi-C H O Calculated,%: C 57.59; H 5.64;
N 11.19.
Example. 26. N-i.4- (2-Imidazol-1-yl) ethoxybenzoyl morpholin.
Sequential treatment of (4-carboxyphenoxy) ethyl imidazole (1.4 g) with thionyl chloride (1.4 g) and morpholine (10 ml) according to example
25 gives (2-imidazol-1-yl) ethoxybenzoyl morpholine, m.p. 109-111 ° С
(from ethyl acetate). Found,%: c 63.80, H 6.401 N 13.87;
Calculated,%: C 63.77; H 6.36; N 13.94
Example 27. (4-Sulfamoylphenoxy) ethyl Zimidazole,
Phosphorus pentachloride (2.08 g) is added carefully to the chlorosulphoxylate (2.91 g) and the resulting solution is cooled to 0 ° C. Next, 1- (2- Phenoxyethyl) imidazole (1.88 g) is added to the solution in order to allow a large amount of gas to be released after each addition. The mixture is heated in a steam bath for 10 minutes, cooled and poured into a mixture of crushed ice and beat a quantity of concentrated ammonia solution. The resulting sticky solid is separated by filtration, washed with water, dried under vacuum and subjected to silica gel chromatography. As a result of the extraction by a mixture of chloroform and methanol (4: 1), a resin is obtained which crystallizes after rubbing. nor with a few milliliters of ethanol to obtain (4-cylphamoyl-phenoxy) ethyl imidazole (0.5 g), m.p. 147.5-148.5С.
Found,%: from 49.57; H 4.93) N 15.36.
Example 28. (4-Ag.shnofenoksi) ethyl imidazole.
Iron powder (6.0 g) is added in portions to a warm solution of 1-H2-(4-nitrophenoxy) ethyl imidazole (3.7 g) in 5 and. hydrochloric acid solution (60 ml). After 20 minutes, the solution is cooled, basified with a dilute sodium hydroxide solution, the mixture is stirred with chloroform and filtered. V The chloroform layer of the filtrate is separated, dried over sodium sulfate and evaporated, resulting in a solid that crystallizes: from a mixture of ethidacetate / gasoline and gives (4-aminophenoxy) ethyl} imidazole (2.25 g), so pl. 91-92 C. Found,%: C 64.35J, H 6.401 N20, 61; C ,, H,., Calculated,%: C 65.01; H 6.45; N 20.68, Example 29. 1-p- {4- Methoxy carbonylaminophenoxy) ethyl} imidazole. Methyl chloroformate (0.5 g) was added to a stirred solution of 1-G2- (4-aminophenoxy) ethyl imidazole (1.6 g) in chloroform (60 ml), the mixture was stirred at room temperature for 2 hours and then evaporated. The residue is dissolved in water and alkalized by the addition of sodium bicarbonate. The resulting precipitate is separated by filtration, washed with water and crystallized from a mixture of methanol / water, resulting in the formation of 1-C2- (4-methoxy-carbonylaminophene si) ethyl imidazole (1.13 g), m.p. 152-153C. Found,%: C 59.77, H 5.81; N 15.92; ZO - - - n with 59.76; Calculated,%: N 16.08. Example 30. 1-G2- (4-UreidoNoxy) ethyl imidazole. 1-C2- (4-laminophenoxy) ethyl imidazole (o, 6 g) is dissolved in 1N. solution of hydrochloric acid (8.0 ml), and then a solution of cyanate kal (0.3 g) in 1 ml of water is added. The mixture is kept at room temperature for 15 minutes and the resulting solid is separated by filtration, washed with water and crystallized from water, resulting in the formation of l-t2- (4-yrepidophenoxy) ethyl imidazole (0.6 g), t pl. 199-; 200s. C 58.20; n 5.70; Found,% N 23.06; H Z C H 5.73; Calculated,%; N 22.75. 31. Chlorohydrate 1P - p and meper - 2- (4-aminomethyl phenoxy) ethyl imide A solution of (4-cyanophenoxy) these imidazole (8.6 g) in dry furan tetrahydro (70 ml) is added dropwise, stirred by a suspension ali lithium hydride (3.8 g) in dry tetragrofuran (150 ml) at reflux temperature. The mixture is stirred for 3 hours at reflux temperature, and then for 18 hours at room temperature. Water (4 ml) and 16 m of 1.25 N are then carefully added. sodium hydroxide solution. The mixture is filtered and the filtrate is evaporated to form an oil, which is subjected to silica gel chromatography. Elution of the column with chloroform / methanol (20: 1) gave pure product (5.7 g) as an oil. A portion of the oil is dissolved in chloroform and treated with an excess amount of gaseous hydrogen chloride. The solid is separated by filtration and crystallized from ethanol to form (4-aminomethylphenoxy) ethyl imidazole chlorohydrate, m.p. 216-217 ° C. Found%: C 49.43 | H 5.94; N 14, bo; Calculated,%: C 49.66; H 5.91, N 14.48. Example 32. 1- 2-l4-L-methyl-aminomethylphenoxy) ethyl imidazole. 1-f2- (4-Lminomethylphenoxy) ethyl-j-imidazole (1.1 g) is heated on a steam bath for 2 hours in a mixture of acetic acid (10 ml) and acetic anhydride (1 ml). The solution is then evaporated and the residue is dissolved in a small volume of water. The resulting solution is alkalinized with sodium bicarbonate, the solid is separated by filtration, washed with water and crystallized from water, resulting in (4-acetylaminomethylphenoxy) ethyl imidazole (0.70 g), mp 115-116 ° C. Example 33. (4-Ureidomethylphenoxy) ethyl imidazole. 1- 2- (4-minomethylphenoxy) ethyl imidazole (1.1 g) is dissolved in 1N. solution of hydrochloric acid (7 ml), and a solution of potassium cyanate (0.5 g) in 1 ml of water was added to the resulting solution. The solution is kept at room temperature for 30 minutes, and then heated for a short period of time to USRS and cooled. The resulting solid is separated by filtration and crystallized twice from water, resulting in 1–4- (2-ureidomethylphenoxy) ethyl imidagol (0.33 g), m.p. 198-199s Found,%: C 58.24; H 6.13 / N 21.96 q H ,, g N2.0 2 Calculated,%: C 59.98; H 6.20, N 21.53. Example 34 (4-Acetylcarbamoylphenoxy) ethyl imidaeol. N, M-Carbonyldiimidazole (4.9 g) was dissolved in dry N, M-dimethylformamide (10 ml) and acetic acid (1.8 g) was added. The solution was stirred for 5 minutes and then 1-f2- ( 4-carbamoylphenoxy) ethyl imldazole (4.6 g). The solution is heated to reflux temperature, which is maintained for 3 hours and then. evaporated. The residue is treated with an aqueous solution of sodium bicarbonate and the mixture is extracted several times with ethyl acetate. The combined ethyl acetate extracts are washed with water, dried over sodium sulfate, and evaporated, resulting in an oil, which is chromatographed on silica gel. Elution of chlorine with the photomm gives some impurities. Further elution with chloroform / methanol (50: 1) gives a solid which crystallizes from 2-butanone, resulting in (4-acetylcarbamoylphenoxy) ethyl} imidazole (0.9 g), m.p. 164-1b5 ° C. Found %: C, 61.28; H 5.54; N 15.51; - (5 ° Calculated,%: C 61.53; H 5.53, N 15.38. Example 35. (4-Benzryl carbamoylphenoxy) ethyl Thymidazole. Treatment of benzoic acid with N, N-carbon-bldiimidazole and (4-carbamoylphonoxy) ethyl imidazole in dry N, M-dimethylformamide according to measure 34 gives (4-benzoylcarbamylphenoxy) ethyl imidazole, mp 152154 (from methanol / ethyl acetate) Found,%: C 67.66; H 5.16, M 12.59; Calculated,%: C, 68.05; H, 5.11; N, 12.53. Example 36. N-Methylsulfonyl-4-2 (4-imidazolyl) ethoxyJbenz carboximidic acid. A mixture of 1- (4 carboxyphenoxy) ethyl imidazole (3 , 3 g), obtained from the added hydrochloride in time To dissolve in water, prepare an alkaline solution using dilute sodium hydroxide followed by precipitation as a result of the addition of acetic acid, and N, N-carbonyldiimidazole (3.0 g) is heated in a steam bath for 2 hours and then methane is added Sulfonamide (3.2 g). The mixture is heated to, which is maintained for 2.5 hours, and then somewhat cooled. The reaction mixture is precipitated upon cooling, is separated by filtration, and the water is washed, resulting in the formation of M-methylene sulfonyl -4-1 2- (4-imidazolyl) ethox benzolkarboksimidova acid, mp 198-199 ° C. Found,%: C 50.37; H 4.84; N 13.67; C NN-15 s045 Calculated,%: C 50.47 / H 4.89; N 13.59. Example 37.M-Benzoylsulfon-4-C2- (1-imidazolyl) ethoxy.benzene carboxamide acid. As a result of treatment with 1-L2 (4carboxyphenoxy) ethyl imidazole Mm carbonyldiimidazole and then with benzenesulfonamide analytically to Example 36, M-benzenesulfonyl-4-12- (1-imidazolyl) ethoxy benzenecarboximidic acid is formed, mp. 250252 C (from a mixture of N, L-dimethylphoamoamide /). Found,%; C 58.17; H 4.60; N 11.08. Calculated,%: C 58.21; H 4.81; N 11.31. Example 38. 1-GZ- (4-Carboxyphenoxy) propyl imidazole. A. Sodium hydride (O, 6 g, 50% suspension in mineral oil is carefully added to a stirred and cooled solution of imidazole (0.79 g) in dry N, M-dimethylformamide (50 ml). After active interaction at the initial stages are heated to for 10 minutes and then stirred at room temperature for another hour. Then ethyl 2- (3-chloropropoxy) benzoate (2.8 g) is added over 2 minutes and the resulting the mixture is heated on a steam bath for 6 hours and then cooled. In order to decompose unreacted sodium hydride is added water (1 ml) and the solution is evaporated, and the residue is chromatographed on silica gel. Elution with chloroform gives mineral oil and small amounts of impurities. Elution with chloroform / methanol (20: 1) gives pure 1- 3 (4-ethoxycarbonylphenoxy a) propyl imidazole as an oil after evaporation of the solvent. B. Ester (0.75 g) is added to a solution of potassium hydroxide (2.0 g) in water (20 ml) and the mixture is heated in a steam bath for 18 h, and then cooled. As a result of the sub-, acidification with acetic acid, a solid is formed, which is separated by filtration and crystallized from water to give 1–3-C4 carboxyphenoxy-propyl imidazole (0.31 g), m.p. 218c. Found,%: C 63.11; H 5.77; N 11.18; C “HM NzO Calculated,%: C 63.41, -H 5.69, N 11.38. Exam 39. (2-Carbamoylmethylphenoxy) ethyl imidazo. A mixture of 1- 2- (2-carbetoxymethylphenoxy) ethyl imidazole (3.5 g) of a concentrated aqueous solution of amgliac (30 ml) and ethanol (10 ml) is heated to 120 ° C for 18 hours in a pressure vessel. The mixture is cooled and evaporated, and the residue in the form of an oil is subjected to silica gel chromatography. Elution with chloroform / methanol (4: 1) gives a solid which crystallises out of the isopropanol / ethyl acetate mixture and results in
I- 2- (2-carbamoylmethylphenoxy) ethyl imidazole (0.7 g), so pl. Ib-IW C. Found,%: C 63.42, H 6.10, N 16.82 ,.
С Н ргзОа
Calculated,%: C 63.6b; H 6.16; N 17.13.
Example 40. H-1; |, iano-4- 2- (1g imidaeolyl) ethoxyZbenzenecarboximidic acid.
As a result of treating (4carboxyphenoxy) ethyl imidazole with N, Ncarbonyldiimidaeol and then with cyanamide in accordance with Example 36, N-cyano-4-2- (1-imidazolyl) ethoxy-Benzenecarboximidic acid is formed, mp. 199-200 ° C with decomposition (from water ;.
Found,%: C 60,59; H 4.64; N 22.20; .Oi
Calculated,%: C 60.93; H 4.72; N 21.87.
Example 41 (4 Carboxyphenoxy) erylJimidazole {1 g) is added to distilled water (900 ml) and the pH is adjusted to 5. with hydrochloric acid. Sodium chloride (1B g) is added to the mixture and the volume of the solution is adjusted to 2 liters. The final solution is sterilized by filtration through an antibacterial filter under sterile conditions and poured into 10 ml glass ampoules.
Example 42. Hydrochloride-1- 2- (4-carboxyphenoxy) ethyl imidazole.
A solution of imidazole (17 g) in N, N-dimethylformamide (100 ml) was added with sodium hydride sludge (21 g, 57% dispersion in oil) in N, H-dimethylformamide (200 ml). The mixture is heated in a steam bath for 15 minutes, cooled, diluted with N, N-dimethylformamide (1.0 L) and then a solution of 4- (2-chloroethoxy) benzene acid (50.1 g) in N, L is added to the mixture. - dimethylformamide (200 ml). The mixture is heated up to 9 5 ° C with KOTOpbie and maintained for 2.5 hours and then cooled, and mixed with ethanol (100 ml) is added to the mixture in order to decompose the excess sodium hydride. Subsequently, 6N hydrochloric acid solution (100 ml) was added to the mixture and the solution was concentrated to a volume of 0.5 l by evaporation under reduced pressure. Acetone (750 ml) is added to the resulting slurry, and the resulting precipitate is separated by filtration. The solid is suspended in a mixture of industrial ethanol.
0 (760 ml) and water (50 ml) and heated to reflux. The solution, while still hot, is filtered and evaporated to dryness under reduced pressure. The residue crystallizes. From;
5-6 N. hydrochloric acid solution, resulting in a crude product (20.8 g). Recrystallization of 10 g from a mixture of industrial ethanol and water gives (4-carboxyphenoxy) ethyl imidazole hydrochloride (6.9 g, 21%)
0 in the form of betelch crystals, so pl. 23924lc, the product is identified with the product of Example 16.
Example 43. (4-Methoxycarbonylphenoxy) ethyl imidazole.
five
The general procedure of Example 42 is carried out, but methyl 4- (2-chloroethoxy) benzoate is used instead of 4- (2-chloroethoxy) benzoic acid. Recrystallization of the product from a mixture of ada.O tone and hexane gives (4-methoxycarbon, ylphenoxy) ethyl imidazole (20.9 g 54%) as white crystals, m.p. 99-100 ° C ,, - V (KVg) 1729, 1715, 1604.
five
Example 44. (4-Carboxyphenoxy) ethyl 1 imidazole.
A solution of (4-methoxycarbonylphenoxy) ethyl Zimidazole (12.3 g) in 6 and. The solution is cooled and the crystalline precipitate is filtered off, washed with acetone and dried, resulting in the formation of (4-carboxyphenoxy) ethyl imide
5 sol hydrochloride (9.0 g, 67%) as white crystals, so pl. 238-241 C.
Table 1
2.2x10
-S
1,0.х10
.-6
1.0x10
-9
4,0x10
four
7 2,500
-710 74,500
4,6x10
3,4x10
-io
3.8x10
-four
10710-
-51, 0x10
6,6x10
Continued table. one
2,200 2,900 260,000
-four
ten
20,000 18,000
(ABOUT
S
h about
(I
in
""
ace about
I
um
U)

权利要求:
Claims (1)
[1]
"S and the claims of the method of obtaining the substituted derivatives of N- (phenoxyalkyl) imidazole o6iiie and formula 1. TQ-ICH, VO-O where R is NO, CN, SO, NH2., Cf-C alkanoyl,,, g, CONHR, CHj CONHR OCHaCONHR, CON {R) 2L, CK2CON (R) 2; OCH2CON (R) 2, NHR,, tetrazolyl, CHji-tetrazolyl or OCH, 2 -tet-j razolil, C -Cx-alkyl, C-Cd-alkoxy or halogen; H or C f-C-alkyl, H, C. | -C alkyl, C-C-alkoxy-noyl, C-C4 alkylsulfonyl, CM, benzoyl or benzosulfunyl, in which the benzene ring may be substituted by one or more CT-CJJ-alkyl groups, C -C-alkoxy 5 .G , or C F, or halogen; or with R f - C - C - alkyl or two R, together with the nitrogen atom to which they are attached, form pyrolidino, piperidino or morpholino / H, C - Cj alkanoyl, C - C - alkoxycarbonyl, carbamoyl .. or C-alkylcarbamoylJ 2 or 3, their salts, distinguishing-. by imidazole exposure to alkaline alla hydride and a compound of the general form Hal-No) .- “- O, n, R and fr have the above meanings, Hal-chloro, bromine, or iodine, isolating the target product in its own form or in the form of salt. Sources of information that are considered in the examination 1. Buhler N. Pearson A. Organic Synthesis, 4.1. M., Mir, 1973, 504

类似技术:

---

公开号 | 公开日 | 专利标题

---

SU878195A3|1981-10-30|Method of preparing substituted derivatives of n-|-amidazole ot their salts

---

US4921998A|1990-05-01|Substituted amino-5,6,7,8-tetrahydronaphthyl-oxyacetic acids, processes for their preparation and their use as medicaments

---

SU1577695A3|1990-07-07|Method of obtaining heterocyclosubstituted tiolunitriles of pharmaceutically acceptable salts thereof

---

US4029673A|1977-06-14|N-| substituted benzamides and derivatives thereof

---

SU1528321A3|1989-12-07|Method of producing indolysine derivatives or pharmaceutically acceptable salts thereof

---

SU1176834A3|1985-08-30|Method of producing derivatives of carbamide

---

CS244423B2|1986-07-17|Method of substituted 1,2-diaminocyclobuten-3,4-dions production

---

SU865125A3|1981-09-15|Method of preparing imidazole derivatives or thir salts

---

SU1110381A3|1984-08-23|Process for preparing derivatives of imidazolyl phenylimidine or their salts

---

DD218890A5|1985-02-20|METHOD OF PREPARING N- | -ALKYL) -ARYLAMIDES

---

US4346097A|1982-08-24|Method for treating convulsions with pyrazole-4-carboxamide derivatives

---

JPH0794417B2|1995-10-11|N-aminobutyl-N-phenylarylamide derivative

---

SU1195903A3|1985-11-30|Method of producing 1-phenyl-2-aminocarbonylindole compounds or their salts of acid connection

---

US4069254A|1978-01-17|ω-|-alkylamine

---

US4001228A|1977-01-04|2-thiol-4,5-diphenyloxazole s-derivatives

---

US5859032A|1999-01-12|Pyridine derivative, anti-ulcer drug, and antibacterial drug

---

US5225410A|1993-07-06|Triazolyl hydrazide derivatives

---

US5753667A|1998-05-19|1-oxo-2- | pentylpiperidine derivatives, their preparation and their therapeutic application

---

US4183937A|1980-01-15|Blood pressure lowering benzoquinolizines

---

IL45995A|1977-06-30|4-pyridylthiazole-2-carboxamides and acetamides their preparation and pharmaceutical compositions containing them

---

US4628083A|1986-12-09|2-hydroxy-5-|-benzene alkanoic acids

---

DE2546319A1|1977-04-28|NEW CYCLOHEXYLPHENYL DERIVATIVES

---

US3105849A|1963-10-01|Bicyclic hydrazinium compounds

---

US5087640A|1992-02-11|Novel cyanoguanidine derivatives

---

US4916149A|1990-04-10|Diuretic and saluretic 4-chloro-3-sulfamoylbenzoic acid hydrazides

同族专利:

---

公开号 | 公开日

---

CH644597A5|1984-08-15|

---

US4602016A|1986-07-22|

---

US4636500A|1987-01-13|

---

JPS5585572A|1980-06-27|

---

CA1108137A|1981-09-01|

---

NL7908899A|1980-06-17|

---

IT1194900B|1988-09-28|

---

KR830001243B1|1983-06-27|

---

SE444937B|1986-05-20|

---

NO153135B|1985-10-14|

---

KR830001242A|1983-04-29|

---

AU517892B2|1981-09-03|

---

DD147943A5|1981-04-29|

---

IL58917A|1984-03-30|

---

FR2444031B1|1983-06-10|

---

GB2038821B|1982-12-08|

---

AR227637A1|1982-11-30|

---

NZ192360A|1982-02-23|

---

EG14227A|1983-12-31|

---

DE2950019A1|1980-07-10|

---

SE7910204L|1980-06-14|

---

FI793868A|1980-06-14|

---

AU5372579A|1980-06-19|

---

IE49318B1|1985-09-18|

---

FI70888C|1986-10-27|

---

YU301879A|1983-01-21|

---

GR73003B|1984-01-24|

---

DK471479A|1980-06-14|

---

NO794069L|1980-06-16|

---

IE792403L|1980-06-13|

---

PL134005B1|1985-07-31|

---

NO153135C|1986-01-22|

---

ATA783379A|1983-07-15|

---

FI70888B|1986-07-18|

---

GB2038821A|1980-07-30|

---

NL177749C|1985-11-18|

---

IT7941669D0|1979-12-11|

---

FR2444031A1|1980-07-11|

---

BE880584A|1980-06-12|

---

HU183016B|1984-04-28|

---

PL220351A1|1980-12-01|

---

PH15056A|1982-06-03|

---

ES8101556A1|1980-12-16|

---

ES486782A0|1980-12-16|

---

LU81985A1|1980-04-22|

---

PT70571A|1980-01-01|

---

ZA796708B|1981-08-26|

---

CS216517B2|1982-11-26|

---

IL58917D0|1980-03-31|

---

JPS585197B2|1983-01-29|

---

AT373879B|1984-02-27|

---

NL177749B|1985-06-17|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US3534061A|1967-12-04|1970-10-13|Parke Davis & Co|N--beta-nitrostyryl)-phenoxyalkyl pyrroles|

---

US4085209A|1975-02-05|1978-04-18|Rohm And Haas Company|Preparation and safening effect of 1-substituted imidazole metal salt complexes|

---

US4078071A|1976-03-08|1978-03-07|Syntex Inc.|Derivatives of substituted N-alkyl imidazoles|

---

JPS5951943B2|1978-08-21|1984-12-17|Kitsusei Yakuhin Kogyo Kk|US4350696A|1980-03-08|1982-09-21|Pfizer Inc.|Imidazole derivatives, process for their preparation and pharmaceutical compositions thereof|

---

US4444775A|1981-06-22|1984-04-24|Ciba-Geigy Corporation|Substituted imidazo[1,5-A]pyridines|

---

DE3148291A1|1981-12-05|1983-06-09|Basf Ag, 6700 Ludwigshafen|UREA DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE FOR CONTROLLING UNWANTED PLANT GROWTH|

---

JPH0222752B2|1981-12-28|1990-05-21|Yamanouchi Pharma Co Ltd|

---

US4588732A|1982-12-21|1986-05-13|Ciba-Geigy Corporation|Certain imidazopyridine derivatives and their use as thromboxane synthetase inhibitors|

---

US4470986A|1982-12-21|1984-09-11|Ciba-Geigy Corporation|Certain imidazopyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors|

---

NL8301550A|1983-05-03|1984-12-03|Gist Brocades Nv|IMIDAZOLETHANOL ESTERS.|

---

US4511573A|1983-05-17|1985-04-16|Ciba-Geigy Corporation|3-Substituted-2- indoles|

---

PH22076A|1983-08-25|1988-05-20|Daiichi Seiyaku Co|Benzocycloalkane derivative|

---

IT1212791B|1983-11-24|1989-11-30|Medea Res Srl|IMIDAZOLIC DERIVATIVES VASODILATOR AND ANTITROMBOTIC ADAPTITY, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.|

---

ES539074A0|1984-12-10|1985-11-16|Ferrer Int|PROCEDURE FOR OBTAINING NEW DERIVATIVES IMIDAZOLILETOXIINDANICOS.|

---

US4894385A|1985-01-16|1990-01-16|Sankyo Company Limited|Imidazole derivatives as inhibitors of TXA2 synthesis|

---

NO166644C|1986-01-28|1991-08-21|Sankyo Co|ANALOGY PROCEDURE FOR THE PREPARATION OF TIAN EVENING DERIVATIVES.|

---

EP0239306B1|1986-03-27|1993-06-02|Merck Frosst Canada Inc.|Tetrahydrocarbazole esters|

---

JPS63179840A|1986-07-24|1988-07-23|Yamanouchi Pharmaceut Co Ltd|Novel chemical substance|

---

AT57925T|1987-04-03|1990-11-15|Cl Pharma|NEW 2-THIENYLOXYACETIC ACID DERIVATIVES, A METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.|

---

JPH0223547B2|1988-09-12|1990-05-24|Yamanouchi Pharma Co Ltd|

---

DE4204686A1|1992-02-17|1993-08-19|Gruenenthal Gmbh|IMIDAZOLYLPHENOL DERIVATIVES, MEDICAMENTS CONTAINING THEREOF, AND A METHOD OF PREPARING THESE COMPOUNDS AND MEDICAMENTS|

---

WO1999045905A2|1998-03-13|1999-09-16|Pozen Inc.|Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists|

---

ES2172436B1|2000-10-31|2004-01-16|Almirall Prodesfarma Sa|INDOLILPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALERGIC AGENTS.|

---

US20050020657A1|2002-07-09|2005-01-27|B.M.R.A. Corporation B.V.|Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxygenase-2|

---

AU2004264722A1|2003-08-07|2005-02-24|B.M.R.A. Corporation B.V.|Compositions and methods involving the combination of a thromboxane A2 receptor antagonist and an inhibitor of cyclooxigenase-1|

---

KR101275814B1|2006-06-23|2013-06-18|삼성에스디아이 주식회사|Dispersant Compound and Method for Producing the Same|

---

US20110015158A1|2007-12-11|2011-01-20|Viamet Pharmaceuticals, Inc.|Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties|

---

CN101811974B|2010-04-15|2012-12-12|合肥医工医药有限公司|4- propoxy)-3, 5-dimethoxy benzoic acid, and preparation method and medical purpose thereof|

---

CN101851209B|2010-06-21|2012-09-19|合肥医工医药有限公司|Imidazole ethyl vanillic acid ether, preparation method and medicinal application thereof|

---

MX2014014234A|2012-05-22|2015-05-07|Genentech Inc|N-substituted benzamides and their use in the treatment of pain.|

---

WO2014066491A1|2012-10-26|2014-05-01|Merck Sharp & Dohme Corp.|N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels|

法律状态:

优先权:

---

申请号 | 申请日 | 专利标题

---

GB7848367|1978-12-13|

---